Thymosin Alpha 1 Explored for Hepatitis C Patients Failing Prior Treatments

Chronic hepatitis C infection is a major cause of chronic liver disease in the United States, with approximately one-third of patients developing cirrhosis, which can lead to liver failure or liver cancer. Current standard treatments for previously untreated patients are successful in only about half of cases. This study addresses the critical lack of established therapy for non-responders who have already failed initial interferon-based treatments.

The study was completed, indicating that data collection concluded. However, specific efficacy results, such as sustained virological response (SVR) rates – defined as undetectable viral RNA 24 weeks after completing treatment – are not provided in the available abstract. The primary objective was likely to assess whether the addition of thymalfasin could significantly improve treatment outcomes compared to PEGinterferon alfa-2a alone in patients who had previously failed interferon-based therapies. > The study aimed to determine if thymalfasin could offer a new therapeutic option for hepatitis C non-responders, a population with limited treatment alternatives at the time. Without detailed results, it is not possible to quantify improvements in viral clearance or other clinical markers. The trial design suggests an intention to identify a more effective regimen for a challenging patient group.